Skip to content

Study · Observational study · n = 40 · 2016

3 results

The Influence of GnRH Analog Therapy on Growth in Central Precocious Puberty.

Głąb E, Wikiera B, Bieniasz J, Barg E

Advances in clinical and experimental medicine : official organ Wroclaw Medical University1 Jan 2016Cited by 17 (Europe PMC)

PMID26935495 (opens in a new tab)DOI10.17219/acem/31433 (opens in a new tab)PepBankPUB-26935495
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, decapeptyl treatment was associated with a decline in height standard deviation score.

    In plain wordsIn girls with central precocious puberty, decapeptyl treatment was linked to a decline in height standard deviation score.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseHeight standard deviation score during treatment
    Study

    n = 40

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    3.75 mg every 28 days · intramuscular · 3.3 ± 2.3 yearsAs given in this study (human).

    Measurements

    Height SDS
    2 SDS
    before treatment
    Height SDS
    1.24 SDS
    during treatment

    Source sentences

    Summary
    During the treatment a decline in HtSDS from 2.0 ± 1.36 to 1.24 ± 1.0 was observed (p = 0.0002)
    2 context sentences
    Summary · context
    The study group consisted of 40 girls with puberty onset aged 6.0 ± 1.9 years (mean, ± SD), treated with 3.75 mg decapeptyl depot intramuscularly every 28 days.
    Summary · context
    The treatment was initiated at the age of 7.5 ± 2.2 years and continued for 3.3 ± 2.3 years, until the age of 11.4 ± 0.9 years.
  2. 02HumanObservational studyEfficacy outcome

    In girls with central precocious puberty, decapeptyl treatment was associated with slower bone maturation.

    In plain wordsIn girls with central precocious puberty, decapeptyl treatment was linked to slower bone maturation.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseBone maturation deceleration
    Study

    n = 40

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    3.75 mg every 28 days · intramuscular · 3.3 ± 2.3 yearsAs given in this study (human).

    Measurements

    Bone maturation deceleration
    1 year
    first year
    Bone maturation deceleration
    0.66 year
    following years

    Source sentences

    Summary
    and a deceleration in the maturation of bones of 1.0 ± 0.29 year in the first year and 0.66 ± 0.33 year in the following years (p = 0.0008).
    2 context sentences
    Summary · context
    The study group consisted of 40 girls with puberty onset aged 6.0 ± 1.9 years (mean, ± SD), treated with 3.75 mg decapeptyl depot intramuscularly every 28 days.
    Summary · context
    The treatment was initiated at the age of 7.5 ± 2.2 years and continued for 3.3 ± 2.3 years, until the age of 11.4 ± 0.9 years.
  3. 03HumanObservational studyEfficacy outcome

    In girls treated with decapeptyl for precocious puberty, final height SDS was higher than the pretreatment prediction.

    In plain wordsIn girls treated with decapeptyl for precocious puberty, final height SDS was higher than the pretreatment prediction.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseFinal height SDS versus pretreatment prediction
    Study

    n = 40

    Comparator
    Pretreatment height prediction
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    3.75 mg every 28 days · intramuscular · 3.3 ± 2.3 yearsAs given in this study (human).

    Measurements

    Height SDS
    1.33 SDS
    end of treatment
    Predicted height SDS
    0.07 SDS
    pretreatment

    Source sentences

    Summary
    The HtSDS at the end of the treatment was significantly higher than was predicted in pretreatment (1.33 ± 1.04 vs. 0.07 ± 1.39, p = 0.0005).
    2 context sentences
    Summary · context
    The study group consisted of 40 girls with puberty onset aged 6.0 ± 1.9 years (mean, ± SD), treated with 3.75 mg decapeptyl depot intramuscularly every 28 days.
    Summary · context
    The treatment was initiated at the age of 7.5 ± 2.2 years and continued for 3.3 ± 2.3 years, until the age of 11.4 ± 0.9 years.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.